phentermine / Generic mfg. - LARVOL DELTA

Bridging Obese Liver Transplant Candidates to Listing: Safety and Efficacy of VLCD Combined With Pharmacotherapy in Decompensated Cirrhosis (ACG 2026) - "Ten initiated VLCD (< 900 kcal/day) with phentermine (n=9) and GLP-1 receptor agonists (n=8; tirzepatide, semaglutide, liraglutide, or dulaglutide). Mean age 62 years; 54% male. Etiologies: MASH (54%), HCV (15%), AIH/PBC (15%), Met-ALD (8%), SSC (8%). 77% had decompensated cirrhosis."

Clinical • CNS Disorders • Fibrosis • Genetic Disorders • Hepatology • Immunology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Transplantation

GLP-1 Analogues and Long-term Outcomes in Adults with Obesity and Elevated CRP: A Real-world Matched Cohort Study. (PubMed, Am J Cardiol) - "Using the TriNetX Global Collaborative Network, adults with body mass index ≥30 kg/m² who received a GLP-1 RA were compared with an active-comparator cohort receiving metformin, orlistat, or phentermine without GLP-1 RA exposure. Ischemic stroke, arrhythmias, and heart failure with reduced ejection fraction were modestly lower, whereas acute myocardial infarction and incident heart failure with preserved ejection fraction did not differ significantly between cohorts. In conclusion, GLP-1 RA exposure was associated with lower long-term composite clinical events among adults with obesity and CRP levels of 3-10 mg/L, predominantly reflecting lower mortality; prospective studies incorporating longitudinal weight and CRP measurements are needed to evaluate potential mediating mechanisms."

Journal • Real-world evidence • Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Inflammation • Ischemic stroke • Myocardial Infarction • Obesity • CRP

PHENTERMINE AND THE FAILING HEART: A CASE OF PHENTERMINE ASSOCIATED CARDIOMYOPATHY COMPLICATED BY PULMONARY HYPERTENSION (CHEST 2026) - No abstract available

Clinical • Cardiomyopathy • Cardiovascular • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

Adaptive Pharmacotherapy in Obesity: Intermittent, Dose-Stratified Phentermine Improves Visceral Adiposity and Body Composition (OBESITY WEEK 2026) - No abstract available

Genetic Disorders • Obesity

Visceral Fat Reduction With Phentermine 30 Mg Predicts Cardiometabolic Improvement:A Real-World Flexible Strategy (OBESITY WEEK 2026) - No abstract available

Clinical • Real-world • Real-world evidence

LEAP Trial: Long-Term Effectiveness of the Obesity Medication Phentermine (OBESITY WEEK 2026) - "(Pajewski) 4 Describe the implications of the LEAP trial results to the prescribing of phentermine for the treatment of obesity in real-world clinical practice settings. (Gudzune) 5 Summarize the background and history related to the use of phentermine for the treatment of obesity (Ard)"

Cardiovascular • Genetic Disorders • Obesity

A Case of Phentermine-Induced Multi-Vessel Coronary Artery Spasm (AHA 2026) - "Abstract is embargoed at this time."

Clinical • Atherosclerosis • Cardiovascular

Trends in preoperative weight loss modalities among patients receiving body contouring surgery. (PubMed, Surg Obes Relat Dis) - "Body contouring patients utilize a variety of surgical and pharmacologic weight loss modalities. Patients using potent weight loss modalities may more frequently undergo abdominal contouring compared to extremity contouring, potentially due to preferential abdominal skin laxity from massive weight loss."

Journal • Aesthetic Medicine • Gastrointestinal Disorder

SMALL BOWEL OBSTRUCTION IN A 38 YEAR OLD FEMALE AFTER INAPPROPRIATE USE OF PHENTERMINE: A CASE REPORT (UEGW 2026) - No abstract available

Case report • Clinical

Severe Hemodynamic Instability After Pneumoperitoneum in a Patient With Recent Phentermine Use and Chronic Labetalol Therapy (ASA 2026) - "After targeted medication reconciliation and extended phentermine discontinuation, repeat surgery proceeded uneventfully. The patient recovered well with an undetectable PSA."

Clinical • Hypotension

Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults. (PubMed, Clin Pharmacol Ther) - "Adults aged ≥ 18 years who are overweight or obese and initiated tirzepatide, GLP-1RAs, or other anti-obesity medications (including orlistat or phentermine) between January 2022 and December 2024 were included...In comparison with other anti-obesity medications, tirzepatide was associated with reduced risks of both CTS (HR 0.75; 95% CI 0.65-0.85) and CTS surgery (HR 0.64; 95% CI 0.44-0.94). In conclusion, Tirzepatide use was associated with reduced risks of CTS, particularly when compared with non-GLP-1RA therapies, suggesting potential metabolic and neuroprotective benefits."

Journal • Diabetes • Genetic Disorders • Metabolic Disorders • Musculoskeletal Pain • Obesity

Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation (clinicaltrials.gov) - P4 | N=60 | Not yet recruiting | Sponsor: Massachusetts General Hospital

New P4 trial • Genetic Disorders • Obesity

A survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management. (PubMed, Obes Pillars) - "Greater comfort was associated with past experiences prescribing phentermine (aOR 4.14, 95% CI 1.69-10.18) and prescribing liraglutide (aOR 2.34, 95% CI 1.05-5.24). Half of all PCPs at an academic medical center are uncomfortable supporting patients' transition from GLP-1-based drugs to alternative weight management treatments following loss of insurance for these agents. Additional resources, including access to ABOM-certified physicians, are needed to support patients facing this common clinical scenario."

Journal • Reimbursement • US reimbursement • Genetic Disorders • Obesity

Successful Conception Following Tirzepatide Therapy in Long-Standing Unexplained Infertility (ENDO 2026) - "Background: Obesity and metabolic syndrome are established contributors to impaired reproductive outcomes...Desiccated thyroid was changed to levothyroxine 125 mcg daily; TSH improved to 2.2 mIU/L at 3 months. Despite lifestyle measures, thyroid optimization, and a phentermine trial, BMI increased to 31 kg/m2...Metformin was started but soon discontinued due to gastrointestinal intolerance... This case provides a clinical correlate to emerging preclinical and observational data that suggests GLP-1 receptor agonist therapy may improve spontaneous and assisted pregnancy rates and obstetric outcomes, even when matched for BMI or comparable weight loss. The patient's successful outcome after years of failed interventions highlights the critical role of metabolic optimization in restoring fertility, particularly in non-PCOS patients. Additionally, the temporal association and the patient's unique profile invite consideration of improved insulin sensitivity, reduced..."

Dyslipidemia • Endocrine Disorders • Genetic Disorders • Gynecology • Infertility • Inflammation • Metabolic Disorders • Obesity • Obstetrics • Polyendocrine Metabolic Ovarian Syndrome • Sexual Disorders

Challenges in the interpretation of amphetamine results: differences of reactivity between immunoassay and immunochromatography. (PubMed, Scand J Clin Lab Invest) - "Samples containing amphetamine derivatives or potentially cross-reactive substances (tetracaine, trazodone, methylphenidate, ritalinic acid, phentermine, procainamide, ephedrine, bisoprolol, and synthetic cathinones) were subsequently analyzed using an IC assay. Given its limited discrimination between amphetamine and methamphetamine, IC results should be reported as 'amphetamine derivatives'. These findings highlight assay-dependent cross-reactivity and the importance of understanding methodological limitations for an accurate interpretation."

Journal

PhITT: Phentermine's Impact on Treatment in Teens (clinicaltrials.gov) - P2 | N=240 | Recruiting | Sponsor: Russell McCulloh, MD | Initiation date: Dec 2025 ➔ Jun 2026 | Not yet recruiting ➔ Recruiting

Enrollment open • Trial initiation date • Genetic Disorders • Obesity

Bilateral Acute Angle Closure Glaucoma Following Phentermine Monotherapy. (PubMed, J Curr Glaucoma Pract) - "To report a case of bilateral acute angle closure glaucoma following phentermine monotherapy after prior topiramate discontinuation, highlighting the ocular risks of widely used weight loss medications, whether prescribed alone or in combination...Bilateral Acute Angle Closure Glaucoma Following Phentermine Monotherapy. J Curr Glaucoma Pract 2026;20(1):31-33."

Journal • Monotherapy • Cardiovascular • CNS Disorders • Diabetes • Glaucoma • Hypertension • Metabolic Disorders • Migraine • Ophthalmology • Pain

Phentermine-Induced Dilated Cardiomyopathy: A Case Report and Review of Literature. (PubMed, Cureus) - "In the 1990s, new-onset valvulopathy and cardiomyopathy as a result of combination therapy with phentermine and fenfluramine were discovered, leading to the discontinuation of this therapy. Aside from associated increases in both heart rate and blood pressure, major cardiovascular side effects have seldom been reported in the literature. We report a case of new-onset non-ischemic dilated cardiomyopathy and moderate to severe mitral valve regurgitation in a patient with greater than two years of exposure to phentermine-topiramate."

Journal • Cardiomyopathy • Cardiovascular • Genetic Disorders • Obesity

The duration of phentermine therapy in the private healthcare sector of South Africa: A retrospective analysis. (PubMed, S Afr Med J) - "The study yielded highly encouraging results, affirming the ST use of phentermine. The evidence of LT use, however, opens new avenues for research. In the private healthcare sector of SA, the DOT with phentermine is not restricted to ST use, and some individuals may be exposed to the potentially harmful consequences accompanying LT therapy with phentermine."

Journal • Retrospective data • Genetic Disorders • Obesity

Tirzepatide Dose–Response Compared with Phentermine 30 mg in Mexican Adults Living with Obesity: A 12-Month Evaluation of Effectiveness, Adherence, and Economic Sustainability (ECO 2026) - "In Mexican adults living with obesity, tirzepatide provides superior dose-dependent weight loss but is associated with progressively reduced adherence driven primarily by economic barriers. Phentermine 30 mg, while less potent pharmacologically, demonstrates greater long-term persistence and superior adherence-adjusted clinical value. These findings support phentermine as a potentially sustainable and scalable therapeutic option in cost-constrained populations, while tirzepatide remains optimal when long-term financial sustainability can be ensured."

Adherence • Clinical • Genetic Disorders • Obesity

Medication-related nephrotic syndrome: a real-world study from 2004 to 2024 based on the Food and Drug Administration Adverse Event Reporting System. (PubMed, Ther Adv Drug Saf) - "Fifty-four medications demonstrated significant positive signals, including 26 antineoplastic medications (ramucirumab, ROR = 33.59), 7 anti-inflammatory medications (sulfasalazine, ROR = 24.74), 2 digestive system medications (famotidine, ROR = 29.28), and 19 other medications (phentermine, ROR = 41.76). This study provides the first large-scale evaluation of MRNS using FAERS. By identifying high-risk medications and characterizing onset-time patterns, these findings offer valuable evidence for early risk recognition and may support improved pharmacovigilance strategies to reduce medication-related kidney injury."

Adverse events • Journal • Real-world evidence • Glomerulonephritis • Nephrology • Oncology • Renal Disease

Extended-Interval Tirzepatide With Phentermine Bridging Versus Intermittent Phentermine in Adults Living with Obesity: 52-Week Outcomes (ECO 2026) - "Across care pathways for adults living with obesity, extended-interval tirzepatide supported by phentermine bridging achieved higher 52-week weight loss and responder rates than lifestyle-only and intermittent phentermine strategies, with pathway-specific persistence and tolerability profiles. These strategies may help align pharmacologic efficacy with real-world affordability constraints in routine practice. Implementation should consider pathway selection, monitoring needs, and persistence-support mechanisms to maximize durable benefit."

Clinical • Genetic Disorders • Obesity

Diet-induced obesity impairs refeeding responses and downregulates lateral septal GLP-1R in male rats: an effect reversed by weight-loss treatment. (PubMed, Front Pharmacol) - "Furthermore, we evaluated LS GLP-1R levels and refeeding behavior after pharmacological (phentermine, an amphetamine derivative) and dietary (switch to control diet) interventions. In conclusion, the chronic exposure to HFD induces sex differences in LS that could be related to pathological mechanisms observed in obesity and to the efficacy of treatment with GLP-1R agonists. Moreover, phentermine, a classic anorectic drug used for short-term weight loss, generates neurobiological adaptations that increase fasting-induced caloric intake, which could be related to the weight regain observed in obese patients."

Journal • Preclinical • Genetic Disorders • Obesity

Long-Term Body-Composition Benefits of Intermittent Phentermine Combined With Structured Lifestyle Therapy: 24-Month Randomized Follow-Up in Adults Living With Overweight or Obesity (ECO 2026) - "Intermittent phentermine integrated into a structured lifestyle program produces superior and durable 24-month improvements in body composition, visceral adiposity, central anthropometry, lean-mass preservation, and weight-loss maintenance compared with lifestyle therapy alone. These findings position cyclical pharmacologic reinforcement as an effective, clinically scalable long-term strategy for chronic obesity management and support its role as a cost-sensitive alternative in real-world settings. Conflicts of Interest & Funding: No conflict of interest"

Clinical • Genetic Disorders • Obesity

Changes in body composition and metabolic markers after treatment with phentermine and a flexible weight-loss strategy and its variations by gender: a six-month longitudinal study (ECO 2026) - "Patients who achieved adherence to phentermine treatment and FWLS after six months showed an association with significant improvements in body composition and cardiometabolic markers. These patterns showed gender-specific differences, highlighting the importance of stratifying values by gender in pharmacological research on obesity."

Longitudinal study • Observational data • Genetic Disorders • Obesity